Epigenetic insights into neuropsychiatric and cognitive symptoms in Parkinson's disease: A DNA co-methylation network analysis

Parkinson’s disease is a highly heterogeneous disorder, encompassing a complex spectrum of clinical presentation including motor, sleep, cognitive and neuropsychiatric symptoms. We aimed to investigate genome-wide DNA methylation networks in post-mortem Parkinson’s disease brain samples and test for region-specific association with common neuropsychiatric and cognitive symptoms. Of traits tested, we identify a co-methylation module in the substantia nigra with significant correlation to depressive symptoms and with ontological enrichment for terms relevant to neuronal and synaptic processes. Notably, expression of the genes annotated to the methylation loci present within this module are found to be significantly enriched in neuronal subtypes within the substantia nigra. These findings highlight the potential involvement of neuronal-specific changes within the substantia nigra with regard to depressive symptoms in Parkinson’s disease.

[1]  P. Passmore,et al.  Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential , 2022, Communications Biology.

[2]  J. Marchini,et al.  Universal clinical Parkinson’s disease axes identify a major influence of neuroinflammation , 2022, Genome Medicine.

[3]  K. Jellinger.  The pathobiological basis of depression in Parkinson disease: challenges and outlooks , 2022, Journal of Neural Transmission.

[4]  L. Guan,et al.  Application of Neurotoxin-Induced Animal Models in the Study of Parkinson’s Disease-Related Depression: Profile and Proposal , 2022, Frontiers in Aging Neuroscience.

[5]  Syeda Sana Samar,et al.  Prodromal depression and subsequent risk of developing Parkinson's disease: a systematic review with meta-analysis. , 2022, Neurodegenerative disease management.

[6]  Evan Z. Macosko,et al.  Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson’s disease , 2022, Nature Neuroscience.

[7]  Alan J. Thomas,et al.  Epigenome-wide association study of human frontal cortex identifies differential methylation in Lewy body pathology , 2021, Nature Communications.

[8]  Parkinson disease-associated cognitive impairment , 2021, Nature Reviews Disease Primers.

[9]  R. Barker,et al.  Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease , 2021, Nature Genetics.

[10]  J. Hardy,et al.  Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets , 2021, JAMA neurology.

[11]  K. Lunnon,et al.  Exploring Beyond the DNA Sequence: A Review of Epigenomic Studies of DNA and Histone Modifications in Dementia , 2020, Current Genetic Medicine Reports.

[12]  Zina M. Ibrahim,et al.  An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene , 2020, Neurobiology of Aging.

[13]  J. Jankovic,et al.  Parkinson’s disease: etiopathogenesis and treatment , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[14]  Wenda Xue,et al.  Crocin Reverses Depression-Like Behavior in Parkinson Disease Mice via VTA-mPFC Pathway , 2020, Molecular Neurobiology.

[15]  Alan J. Thomas,et al.  A meta-analysis of epigenome-wide association studies in Alzheimer’s disease highlights novel differentially methylated loci across cortex , 2020, Nature Communications.

[16]  E. Henderson,et al.  Neuropsychiatric symptoms in Parkinson's disease: aetiology, diagnosis and treatment , 2020, BJPsych Advances.

[17]  J. Mill,et al.  Psychosis-associated DNA methylomic variation in Alzheimer's disease cortex , 2020, Neurobiology of Aging.

[18]  Juan I. Young,et al.  Genome-wide brain DNA methylation analysis suggests epigenetic reprogramming in Parkinson disease , 2019, Neurology: Genetics.

[19]  S. Horvath,et al.  Longitudinal Epigenome-Wide Methylation Study of Cognitive Decline and Motor Progression in Parkinson's Disease. , 2019, Journal of Parkinson's disease.

[20]  Alan J. Thomas,et al.  Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders , 2019, Brain pathology.

[21]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[22]  R. Barker,et al.  The clinical heterogeneity of Parkinson's disease and its therapeutic implications , 2018, The European journal of neuroscience.

[23]  D. Aarsland,et al.  Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta‐analyses , 2018, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[24]  Yadong Wang,et al.  A framework for analyzing DNA methylation data from Illumina Infinium HumanMethylation450 BeadChip , 2018, BMC Bioinformatics.

[25]  M. Kuijf,et al.  Prevalence of anxiety in Parkinson's disease: A systematic review and meta‐analysis , 2016, Movement disorders : official journal of the Movement Disorder Society.

[26]  C. Allis,et al.  The molecular hallmarks of epigenetic control , 2016, Nature Reviews Genetics.

[27]  Seth G. N. Grant,et al.  Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type Enrichment , 2016, Front. Neurosci..

[28]  A. Verkhratsky,et al.  Decrease of gene expression of astrocytic 5-HT2B receptors parallels development of depressive phenotype in a mouse model of Parkinson’s disease , 2015, Front. Cell. Neurosci..

[29]  N. Kandiah,et al.  Influence of depression in mild Parkinson's disease on longitudinal motor and cognitive function. , 2015, Parkinsonism & related disorders.

[30]  A. Nordström,et al.  Depression and subsequent risk of Parkinson disease , 2015, Neurology.

[31]  Edo Richard,et al.  Apathy in Parkinson's disease: A systematic review and meta‐analysis , 2015, Movement disorders : official journal of the Movement Disorder Society.

[32]  D. Bennett,et al.  Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease , 2014, Nature Neuroscience.

[33]  Ruth Pidsley,et al.  A data-driven approach to preprocessing Illumina 450K methylation array data , 2013, BMC Genomics.

[34]  J. Mill,et al.  A data-driven approach to preprocessing Illumina 450K methylation array data , 2013, BMC Genomics.

[35]  L. Coin,et al.  Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  Matko Bosnjak,et al.  REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.

[37]  Guido Alves,et al.  Epidemiology of psychosis in Parkinson's disease , 2010, Journal of the Neurological Sciences.

[38]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[39]  J. Jankovic.  Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[40]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[41]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[42]  J A Knottnerus,et al.  Increased risk of Parkinson’s disease after depression: A retrospective cohort study , 2002, Neurology.

[43]  D. Aarsland,et al.  Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study , 2000, Journal of the American Geriatrics Society.

[44]  J. Cummings,et al.  Range of neuropsychiatric disturbances in patients with Parkinson’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[45]  A. Kurz,et al.  Predictors of nursing home placement in patients with alzheimer's disease , 1993 .

[46]  Dag Aarsland,et al.  Depression in Parkinson disease—epidemiology, mechanisms and management , 2011, Nature Reviews Neurology.

[47]  V. Haroutunian,et al.  The neuropathological basis for depression in Parkinson's disease. , 2009, Parkinsonism & related disorders.